Efficacy and safety of remimazolam tosylate combined with sufentanil for sedo-analgesia in elderly patients undergoing percutaneous vertebroplasty: A randomized controlled trial
This randomized controlled trial demonstrates that remimazolam tosylate combined with sufentanil provides effective light sedation and superior hemodynamic stability without increasing the risk of postoperative delirium in elderly patients undergoing percutaneous vertebroplasty.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of older adults, a broken bone in the spine is a quiet crisis. Osteoporosis, a condition where bones become brittle and fragile, can cause a vertebra to collapse under the weight of the body, leading to severe pain and a loss of mobility. To fix this, doctors often perform a minimally invasive procedure called percutaneous vertebroplasty. In this surgery, a needle is guided into the fractured bone, and a special cement is injected to stabilize it. While the procedure is quick and effective, it is typically done while the patient is awake, receiving only local anesthesia to numb the skin. For an elderly person, lying still in a cold operating room while hearing the sounds of surgery and feeling the pressure of the injection can trigger intense anxiety. This fear is not just uncomfortable; it can cause the heart to race and blood pressure to spike, creating a dangerous situation for someone whose body is already fragile. The medical community has long sought a way to calm these patients without putting them to sleep or risking their breathing, a balance that is notoriously difficult to strike with older adults.
Researchers at West China Hospital and Jintang First People's Hospital in China set out to test a new approach to this problem. They focused on a relatively new drug called remimazolam tosylate, a sedative designed to work quickly and leave the body just as fast. Unlike older sedatives that can linger in the system and cause confusion or prolonged grogginess, this new drug is broken down by the body's own enzymes into harmless byproducts, regardless of how well a patient's liver or kidneys are working. The team wanted to see if using this drug, combined with a painkiller, could keep elderly patients calm and comfortable during the vertebroplasty procedure without causing the side effects that often plague geriatric anesthesia. They recruited 78 patients between the ages of 60 and 90, all scheduled for the surgery, and split them into two groups. One group received the new sedative, while the other group received a volume-matched infusion of 0.9% normal saline, with both groups getting the same dose of pain medication. Neither the patients nor the doctors assessing the outcomes knew who was in which group, ensuring the results would be objective.
The results showed a clear difference in how the patients handled the stress of the surgery. In the group receiving the new sedative, blood pressure remained remarkably steady throughout the procedure. Even when the surgeons inserted the needle or injected the cement—moments that usually cause a sharp rise in blood pressure due to pain and fear—the patients in the sedative group stayed calm. Their blood pressure dipped slightly after the drug was given but stayed within a safe, healthy range, avoiding the wild swings seen in the other group. The patients who received the sedative were assessed by clinicians to be in a state of light sleep; they were relaxed and conscious during the procedure, yet they could still be easily woken up if needed. In contrast, the patients who did not receive the sedative remained fully alert, often showing signs of distress and anxiety as the surgery progressed. This suggests that the drug successfully provided a "comfortable" state where the patient is sedated but not deeply unconscious, which is often the ideal goal for minor surgeries.
Safety was the other major concern, particularly regarding the brain and the lungs. Elderly patients are at a higher risk for postoperative delirium, a state of acute confusion that can occur after surgery, and for breathing problems caused by strong sedatives. The study found that the new drug did not increase the risk of either. At six and twenty-four hours after the surgery, the mental status of patients in both groups was identical, with no signs of delirium in either group. While a small number of patients in the sedative group experienced brief episodes of shallow breathing or a drop in oxygen levels, these issues were mild and resolved immediately with simple adjustments, such as giving them a little more oxygen or gently encouraging them to breathe deeper. No serious heart or lung complications occurred, though one patient in the sedative group required conversion to general anesthesia and was excluded from the final analysis.
The study concludes that this new sedative offers a promising way to manage pain and anxiety for older adults undergoing spinal surgery. It provides a stable environment where the patient's vital signs do not fluctuate wildly, and the mind remains clear once the procedure is over. While the researchers noted that their study was conducted at a single center and involved a relatively small number of people, the findings suggest that this drug could become a standard tool for making difficult surgeries more tolerable for the aging population. By keeping the body calm and the mind clear, the drug addresses a critical gap in care, turning a frightening experience into a manageable one without the heavy toll of traditional anesthesia.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.